AIM: We investigated the gender-specific control of cardiovascular (CV) risk factors and subclinical vascular lesions in a founder population in Italy. METHODS AND RESULTS: 6148 subjects were enrolled (aged 14-102 years) from four towns. Hypertension (HT), diabetes mellitus (DM) and dyslipidemia (LIP) were defined in accordance with guidelines. A self-reported diagnosis defined awareness of these conditions, and the current use of specific medications as treatment. Prevalence was HT 29.2%, DM 4.8%, LIP 44.1% and was higher in men than in women. Disease prevalence increased with age for every CV risk factor. Men were less likely than women to take anti-HT drugs and to reach BP control (9.9% vs. 16%). Only 17.6% of HT > 65 years had a BP < or =140/90 mmHg, though 48.5% were treated. The use of statins was very low (<1/3 of eligible subjects > 65 years, those with the highest treatment rate). The ratio of control-to-treated HT was lower in subjects with, than in those without, thicker carotid arteries (31.5% vs. 38.8%, p < 0.05) or stiffer aortas (26.0% vs. 40.0%, p < 0.05) or carotid plaques (26.3% vs. 41.1%, p<0.05). CONCLUSION: A large number of subjects at high CV risk are not treated and the management of subclinical vascular lesions is far from optimal.
AIM: We investigated the gender-specific control of cardiovascular (CV) risk factors and subclinical vascular lesions in a founder population in Italy. METHODS AND RESULTS: 6148 subjects were enrolled (aged 14-102 years) from four towns. Hypertension (HT), diabetes mellitus (DM) and dyslipidemia (LIP) were defined in accordance with guidelines. A self-reported diagnosis defined awareness of these conditions, and the current use of specific medications as treatment. Prevalence was HT 29.2%, DM 4.8%, LIP 44.1% and was higher in men than in women. Disease prevalence increased with age for every CV risk factor. Men were less likely than women to take anti-HT drugs and to reach BP control (9.9% vs. 16%). Only 17.6% of HT > 65 years had a BP < or =140/90 mmHg, though 48.5% were treated. The use of statins was very low (<1/3 of eligible subjects > 65 years, those with the highest treatment rate). The ratio of control-to-treated HT was lower in subjects with, than in those without, thicker carotid arteries (31.5% vs. 38.8%, p < 0.05) or stiffer aortas (26.0% vs. 40.0%, p < 0.05) or carotid plaques (26.3% vs. 41.1%, p<0.05). CONCLUSION: A large number of subjects at high CV risk are not treated and the management of subclinical vascular lesions is far from optimal.
Authors: M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: Riitta L Antikainen; Vladislav A Moltchanov; Chrysanthus Chukwuma; Kari A Kuulasmaa; Pedro M Marques-Vidal; Susana Sans; Lars Wilhelmsen; Jaakko O Tuomilehto Journal: Eur J Cardiovasc Prev Rehabil Date: 2006-02
Authors: Cristen J Willer; Serena Sanna; Anne U Jackson; Angelo Scuteri; Lori L Bonnycastle; Robert Clarke; Simon C Heath; Nicholas J Timpson; Samer S Najjar; Heather M Stringham; James Strait; William L Duren; Andrea Maschio; Fabio Busonero; Antonella Mulas; Giuseppe Albai; Amy J Swift; Mario A Morken; Narisu Narisu; Derrick Bennett; Sarah Parish; Haiqing Shen; Pilar Galan; Pierre Meneton; Serge Hercberg; Diana Zelenika; Wei-Min Chen; Yun Li; Laura J Scott; Paul A Scheet; Jouko Sundvall; Richard M Watanabe; Ramaiah Nagaraja; Shah Ebrahim; Debbie A Lawlor; Yoav Ben-Shlomo; George Davey-Smith; Alan R Shuldiner; Rory Collins; Richard N Bergman; Manuela Uda; Jaakko Tuomilehto; Antonio Cao; Francis S Collins; Edward Lakatta; G Mark Lathrop; Michael Boehnke; David Schlessinger; Karen L Mohlke; Gonçalo R Abecasis Journal: Nat Genet Date: 2008-01-13 Impact factor: 38.330
Authors: Angelo Scuteri; Serena Sanna; Wei-Min Chen; Manuela Uda; Giuseppe Albai; James Strait; Samer Najjar; Ramaiah Nagaraja; Marco Orrú; Gianluca Usala; Mariano Dei; Sandra Lai; Andrea Maschio; Fabio Busonero; Antonella Mulas; Georg B Ehret; Ashley A Fink; Alan B Weder; Richard S Cooper; Pilar Galan; Aravinda Chakravarti; David Schlessinger; Antonio Cao; Edward Lakatta; Gonçalo R Abecasis Journal: PLoS Genet Date: 2007-07 Impact factor: 5.917
Authors: Alessandro P Delitala; Marco Orrù; Fabiana Filigheddu; Maria Grazia Pilia; Giuseppe Delitala; Antonello Ganau; Pier Sergio Saba; Federica Decandia; Angelo Scuteri; Michele Marongiu; Edward G Lakatta; James Strait; Francesco Cucca Journal: Clin Endocrinol (Oxf) Date: 2014-07-14 Impact factor: 3.478
Authors: Angelo Scuteri; Christopher H Morrell; Marco Orru'; Majid AlGhatrif; Pier Sergio Saba; Antonio Terracciano; Liana Anna Pina Ferreli; Francesco Loi; Michele Marongiu; Maria Grazia Pilia; Alessandro Delitala; Kirill V Tarasov; David Schlessinger; Antonello Ganau; Francesco Cucca; Edward G Lakatta Journal: Int J Cardiol Date: 2016-05-03 Impact factor: 4.164
Authors: Angelo Scuteri; Marco Orru'; Christopher H Morrell; Kirill Tarasov; David Schlessinger; Manuela Uda; Edward G Lakatta Journal: Atherosclerosis Date: 2011-12-14 Impact factor: 5.162
Authors: Angelo Scuteri; Marco Orru; Christopher Morrell; Maria Grazia Piras; Dennis Taub; David Schlessinger; Manuela Uda; Edward G Lakatta Journal: Atherosclerosis Date: 2010-12-30 Impact factor: 5.162
Authors: A P Delitala; F Filigheddu; M Orrù; M AlGhatrif; M Steri; M G Pilia; A Scuteri; M Lobina; M G Piras; G Delitala; E G Lakatta; D Schlessinger; F Cucca Journal: Nutr Metab Cardiovasc Dis Date: 2015-10-21 Impact factor: 4.222
Authors: Angelo Scuteri; Christopher H Morrell; Marco Orrù; James B Strait; Kirill V Tarasov; Liana Anna Pina Ferreli; Francesco Loi; Maria Grazia Pilia; Alessandro Delitala; Harold Spurgeon; Samer S Najjar; Majd AlGhatrif; Edward G Lakatta Journal: Hypertension Date: 2014-09-15 Impact factor: 10.190